Jennifer Miao1, Shi Huang2, Yan Ru Su3, Carrie A Lenneman4, Meera Wright5, Frank E Harrell2, Douglas B Sawyer6, Daniel J Lenihan7. 1. a Vanderbilt University Medical Center , Nashville , TN , USA. 2. b Department of Biostatistics , Vanderbilt University Medical Center , Nashville , TN , USA. 3. c Division of Cardiovascular Medicine , Vanderbilt University Medical Center , Nashville , TN , USA. 4. d Division of Cardiovascular Medicine , University of Alabama at Birmingham , Birmingham , AL , USA. 5. e St. Thomas Health , Nashville , TN , USA. 6. f Maine Medical Center , Center for Molecular Medicine , Scarborough , ME , USA. 7. g Cardiovascular Division , Washington University in St. Louis , St. Louis , MO , USA.
Abstract
CONTEXT: Improved left ventricular ejection fraction (LVEF) following administration of recombinant human Neuregulin-1β (NRG), epidermal growth factor (EGF) involved in cardiomyocyte repair/survival, has been observed in patients with systolic heart failure (HF). METHODS: Serum NRG was measured by ELISA in 248 patients with NYHA class I-IV HF. RESULTS: NRG exhibited a marginally significant effect on LVEF trajectory over 11 months (p = 0.07). There is no apparent level of NRG that predicts improved survival. CONCLUSIONS: There is a potential relationship between serum NRG and improved LVEF, indicating the need to investigate the utility of NRG in predicting HF outcomes, including LVEF maintenance.
CONTEXT: Improved left ventricular ejection fraction (LVEF) following administration of recombinant humanNeuregulin-1β (NRG), epidermal growth factor (EGF) involved in cardiomyocyte repair/survival, has been observed in patients with systolic heart failure (HF). METHODS: Serum NRG was measured by ELISA in 248 patients with NYHA class I-IV HF. RESULTS: NRG exhibited a marginally significant effect on LVEF trajectory over 11 months (p = 0.07). There is no apparent level of NRG that predicts improved survival. CONCLUSIONS: There is a potential relationship between serum NRG and improved LVEF, indicating the need to investigate the utility of NRG in predicting HF outcomes, including LVEF maintenance.
Entities:
Keywords:
Neuregulin-1; cardiomyopathy; heart failure; left ventricular ejection fraction; left ventricular systolic dysfunction
Authors: Andrew Jabbour; Christopher S Hayward; Anne M Keogh; Eugene Kotlyar; Jane A McCrohon; John F England; Raul Amor; Xifu Liu; Xin Yan Li; Ming Dong Zhou; Robert M Graham; Peter S Macdonald Journal: Eur J Heart Fail Date: 2010-09-01 Impact factor: 15.534
Authors: Nadia Hedhli; Qunhua Huang; April Kalinowski; Monica Palmeri; Xiaoyue Hu; Raymond R Russell; Kerry S Russell Journal: Circulation Date: 2011-05-09 Impact factor: 29.690
Authors: Tom J Parry; Anindita Ganguly; Erika L Troy; J Luis Guerrero; Jennifer F Iaci; Maya Srinivas; Andrea M Vecchione; Donald C Button; Craig S Hackett; Ronald Zolty; Douglas B Sawyer; Anthony O Caggiano Journal: Eur J Pharmacol Date: 2016-12-16 Impact factor: 4.432
Authors: Daniel J Lenihan; Sarah A Anderson; Carrie Geisberg Lenneman; Evan Brittain; James A S Muldowney; Lisa Mendes; Ping Z Zhao; Jennifer Iaci; Stephen Frohwein; Ronald Zolty; Andrew Eisen; Douglas B Sawyer; Anthony O Caggiano Journal: JACC Basic Transl Sci Date: 2016-12-26
Authors: Camilla Hage; Eva Wärdell; Cecilia Linde; Erwan Donal; Carolyn S P Lam; Claude Daubert; Lars H Lund; Agneta Månsson-Broberg Journal: ESC Heart Fail Date: 2020-01-24